Browsing by Subject "interferon"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    New treatment alternatives in the management of non-i̇nfectious i̇ntraocular i̇nflammations: Biologic agents; [Enfeksiyöz olmayan i̇ntraoküler i̇nflamasyonlarin kontrolünde yeni seçenekler: Biyolojik ajanlar]
    (2011) Emre S.; Tutkun I.T.
    Conventional immunosuppressive agents have been traditionally used for the treatment of noninfectious uveitis. Recent developments in genetic engineering have made it possible to synthesize proteins that target specific molecules playing role in the inflammatory response. These agents are generally in protein structure and are named biologic agents. While there is limited experience with biologics in the field of ophthalmology, they are commonly used in other disciplines such as rheumatology and dermatology. Although considerable data have accumulated in the uveitis literature regarding the use of biologic agents, including mainly interferon, infliximab, and adalimumab, their use for this indication is still off-label. Moreover, there are certain precautions that have to be taken into account, as well as important safety issues associated with their use. The purpose of this paper is to present an updated comprehensive review of biologic agents that may be used for the treatment of refractory uveitis.
  • No Thumbnail Available
    Item
    Treatment of mucocutaneous manifestations of behcet's disease; [Behçet hastaliǧi mukokutanöz bulgularinda tedavi̇]
    (2011) Inanr I.; Saçar H.
    Behçet's disease (BD) is a chronic recurrent vasculitis with an unclear etiology. In addition to typical oral, genital and ocular lesions, it involves many organs and systems mainly vascular articular, vascular and neurological ones. Mucocutaneous manifestations are the most frequent and have an important role in diagnosis. In this article, treatment alternatives for mucocutaneous involvement of BD are reviewed.
  • No Thumbnail Available
    Item
    Nonmelanoma Skin Cancer of the Head and Neck: Nonsurgical Treatment
    (2012) Ermertcan A.T.; Hellings P.W.; Cingi C.
    Nonmelanoma skin cancer (NMSC) is one of the most prevalent types of cancer worldwide, with basal cell carcinoma and squamous cell carcinoma being the most frequent histologic types. Surgical excision remains the mainstay of treatment, but nonsurgical treatment options may be indicated in specific cases. Nonsurgical treatment options for NMSC may be preferred as good alternatives under certain circumstances. This review provides a comprehensive overview of the nonsurgical treatment modalities for NMSCs, such as curettage and electrodesiccation, cryotherapy, radiotherapy, laser, photodynamic therapy, immunotherapy, and retinoid therapy. © 2012 Elsevier Inc.
  • No Thumbnail Available
    Item
    Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: Twenty-four year Turkish experience in cladribine therapy
    (John Wiley and Sons Ltd, 2015) Hacioglu S.; Bilen Y.; Eser A.; Sivgin S.; Gurkan E.; Yildirim R.; Aydogdu I.; Dogu M.H.; Yilmaz M.; Kayikci O.; Tombak A.; Kuku I.; Celebi H.; Akay M.O.; Esen R.; Korkmaz S.; Keskin A.
    In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. © 2015 John Wiley & Sons, Ltd.
  • No Thumbnail Available
    Item
    The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma
    (Lippincott Williams and Wilkins, 2024) Arak H.; Erkiliç S.; Yaslikaya Ş.; Eylemer Mocan E.; Aktaş G.; Özdemir M.; Semiz H.S.; Kiliçkap S.; Özalp F.R.; Sever Ö.N.; Akdaǧ G.; Aǧaoǧlu A.B.; Özçelik M.; Sari M.; Arcagök M.; Anik H.; Yayla Ş.B.; Sever N.; Açar F.P.; Bayrakçi İ.; Turhal S.; Ayhan M.; Kuş T.
    Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies. © 2024 Lippincott Williams and Wilkins. All rights reserved.